Zusammenfassung
Die Tumorkachexie stellt ein multifaktoriell bedingtes Syndrom dar, welches mit einem Abbau von Muskel- und Fettmasse einhergeht und bei etwa 50–80 % der Krebspatienten, abhängig von der Art der Tumorerkrankung, auftritt. Es wird angenommen, dass etwa 20 % der Tumorpatienten indirekt an den Folgen der Kachexie versterben. Vor diesem Hintergrund wird verständlich, wie wichtig Kenntnisse zur Pathophysiologie der Tumorkachexie im Hinblick auf die Behandlung von Tumorpatienten sind. Im Folgenden werden die Mechanismen besprochen, die zu einer tumorbedingten Kachexie beitragen.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
Agustsson T, Ryden M, Hoffstedt J, et al. Mechanism of increased lipolysis in cancer cachexia. Cancer Res 2007;67:5531–5537.
Akamizu T, Kangawa K. Ghrelin for cachexia. J Cachexia Sarcopenia Muscle 2010;1:169–176.
Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer 2014;14:754–762.
Asp ML, Tian M, Wendel AA, Belury MA. Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice. Int J Cancer 2010;126:756–763.
Blauwhoff-Buskermolen S, Versteeg KS, de van der Schueren MA, et al. Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer. J Clin Oncol 2016;34:1339–1344.
Blum D, Omlin A, Baracos VE, et al. Cancer cachexia: a systematic literature review of items and domains associated with involuntary weight loss in cancer. Crit Rev Oncol Hematol 2011;80:114–144.
Bonetto A, Aydogdu T, Jin X, et al. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab 2012;303:E410–421.
Constantinou C, Fontes de Oliveira CC, Mintzopoulos D, et al. Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia. Int J Mol Med 2011;27:15–24.
Ezeoke CC, Morley JE. Pathophysiology of anorexia in the cancer cachexia syndrome. J Cachexia Sarcopenia Muscle 2015;6:287–302.
Fukawa T, Yan-Jiang BC, Min-Wen JC, et al. Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia. Nat Med 2016;22:666–671.
Kalra PR, Tigas S. Regulation of lipolysis: natriuretic peptides and the development of cachexia. Int J Cardiol 2002;85:125–132.
Kir S, Spiegelman BM. Cachexia and Brown Fat: A Burning Issue in Cancer. Trends in Cancer 2016;2:461–463.
Kir S, White JP, Kleiner S, et al. Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature 2014;513:100–104.
Le Bricon T, Gugins S, Cynober L, Baracos VE. Negative impact of cancer chemotherapy on protein metabolism in healthy and tumor-bearing rats. Metabolism 1995;44:1340–1348.
Petruzzelli M, Schweiger M, Schreiber R, et al. A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab 2014;20:433–447.
Prado CM, Cushen SJ, Orsso CE, Ryan AM. Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact. Proc Nutr Soc 2016;75:188–198.
Proctor MJ, Morrison DS, Talwar D, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer 2011;104:726–734.
Rohm M, Schafer M, Laurent V, et al. An AMP-activated protein kinase-stabilizing peptide ameliorates adipose tissue wasting in cancer cachexia in mice. Nat Med 2016;22:1120–1130.
Russell ST, Zimmerman TP, Domin BA, Tisdale MJ. Induction of lipolysis in vitro and loss of body fat in vivo by zinc-alpha2-glycoprotein. Biochim Biophys Acta 2004;1636:59–68.
Sanders PM, Tisdale MJ. Effect of zinc-alpha2-glycoprotein (ZAG) on expression of uncoupling proteins in skeletal muscle and adipose tissue. Cancer Lett 2004;212:71–81.
Sassoon DA. Fatty acid metabolism-the first trigger for cachexia? Nat Med 2016;22:584–585.
Sengenes C, Bouloumie A, Hauner H, et al. Involvement of a cGMP-dependent pathway in the natriuretic peptide-mediated hormone-sensitive lipase phosphorylation in human adipocytes. J Biol Chem 2003;278:48617–48626.
Shellock FG, Riedinger MS, Fishbein MC. Brown adipose tissue in cancer patients: possible cause of cancer-induced cachexia. J Cancer Res Clin Oncol 1986;111:82–85.
Tan BH, Fearon KC. Cytokine gene polymorphisms and susceptibility to cachexia. Curr Opin Support Palliat Care 2010;4:243–248.
Tsoli M, Moore M, Burg D, et al. Activation of thermogenesis in brown adipose tissue and dysregulated lipid metabolism associated with cancer cachexia in mice. Cancer research 2012;72:4372–4382.
Tsoli M, Robertson G. Cancer cachexia: malignant inflammation, tumorkines, and metabolic mayhem. Trends in endocrinology and metabolism: TEM 2013; 24:174–183.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Medizin Verlag GmbH, München
About this chapter
Cite this chapter
Hacker, U. (2017). Pathophysiologie der Tumorkachexie. In: Kachexie bei Tumorerkrankungen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-89935-305-1_2
Download citation
DOI: https://doi.org/10.1007/978-3-89935-305-1_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-89935-304-4
Online ISBN: 978-3-89935-305-1
eBook Packages: Medicine (German Language)